Download BIOGRAPHICAL SKETCH

Principal Investigator/Program Director (Last, first, middle)
Lynch, Thomas J.
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed on Form Page 2.
Follow sample format for each person. DO NOT EXCEED FOUR PAGES.
NAME
Howard S. Hochster, M.D.
POSITION TITLE
Professor of Medicine
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
YEAR
INSTITUTION AND LOCATION
DEGREE
CONFERRED
FIELD OF STUDY
Yale University, New Haven, CT
B.S.
1976
Chemistry
Yale University, New Haven, CT
M.S.
1976
Chemistry
Yale University School of Medicine, New Haven, CT
M.D.
1980
Medicine
A. Personnal Statement
Dr. Howard Hochster serves the Yale Cancer Center as Associate Director for Clinical Research. Dr
Hochster has a long record of clinical trial experience and publications relating to new drug development in
medical oncology. He published widely on the use of topoisomerase-1 inhibitior and developed
pharmacodynamic measures in conjunction with improved drug scheduling. He has investigated
intracellular pharmacology of gemcitabine metabolism in clinical trials using PBMC tissue and 19F
Magnetic Resonance Spectroscopy (for which he was recently awarded an R0-1 grant). He has published
numerous phase II and III trials both investigator initiated and through ECOG, where he has been a major
contributor.
Dr Hochster will lead the clinical research efforts at the YCC. In this role his goals are to improve the
research support infracstructure for day to day clinical trail accrual. He will streamline and further support
the protocol development process and regulatory approval process. He will encourage and develop
translationally based investigator initiated trials by securing tissue access coupled to robust clinical data
and assist investigators in securing funding for such trials. Finally we will improve our cooperative group
participation and use key cooperative group protocols to serve as the foundation for invigorating and
expanding a regional network of collaborating physicians and institutions in the Yale Cancer Network. In
the next few years we expect to double therapeutic trial accrual.
B. Positions and Honors
Positions and Employment
1980-1983
Internship and Residency in Internal Medicine, New York University-Bellevue Hospital,
NY, NY.
1983-1986
Fellowship, Divisions of Hematology and Oncology, NYU School of Medicine, NY.
1985-1986
Visiting Fellow, Jules Bordet Institute, Brussels, Belgium
1986-1989
Instructor of Medicine, Department of Medicine, New York University Medical Center, NY.
1986-present NYU Tisch Hospital, Attending Physician, New York University Medical Center, NY.
1986-present Attending Physician, Bellevue Hospital Center, NY, NY.
1989-1995
Assistant Professor of Medicine, Department of Medicine, NYU Medical Center, NY.
1995-2003
Associate Professor of Clinical Medicine, Department of Medicine, NYU SOM, NY.
2000-2003
Associate Professor of Clinical Pharmacology, Dept of Medicine, NYU SOM, NY.
2003-present Professor of Medicine and Clinical Pharmacology, Department of Medicine, NYU SOM,
NY.
2003-present Director, NYU Cancer Institute Clinical Trials Office
2005- 2006
Ad Hoc Member, Clincal Oncololgy (CONC) study section NIH
2007 Member, CONC study section
2009-2011
American Society of Clinical Oncology Scientific Program Committee member (colorectal
cancer chair 2010)
C. Selected peer-reviewed publications (in chronological order).
1. Hochster HS, Plimack ER, Mandeli J, Wadler S, Runowicz C, Goldberg G, Speyer J, Wallach R,
Muggia F; for the New York Gynecologic Oncology Group (and phase II consortium) and the Eastern
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle)
2.
3.
4.
5.
Lynch, Thomas J.
Cooperative Oncology. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian
cancer: An NYGOG and ECOG study. Gynecol Oncol 2005 Oct 24 (Epub ahead of print)
Hochster HS. Capecitabine plus oxaliplatin vs infusional 5FU plus oxaliplatin. Con: Pumpin’ FU (or
avoiding that oral fixation). Clin Adv Hematol Oncol, 2005 May 3(5): 405-406.
Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan RK, Macdonald J, Hong S, John
w Schmoll HJ. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with
advanced colorectal cancer. Clin Colorectal Cancer 2005, Nov 5(4): 257-62.
Hochster HS, Haller DG, deGramont A, Berlin JD, Philip PA, Moore MJ and Ajani JA. Consensus
Report of The International Society of Gastrointestinal Oncology on Therapeutic Progress in Advanced
Pancreatic Cancer. Cancer, 107(4):676-685, 2006.
Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with
metastatic colorectal cancer. Semin Oncol. Oct;33(5 Suppl 10):S8-14. 2006.
6. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related
neurotoxicity. J Clin Oncol. 25(25):4028-9. 2007
7. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen
M, Quinones M, Morse M, Chen HX. Randomized phase II trial of cetuximab, bevacizumab, and
irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer:
the BOND-2 study. J Clin Oncol 25(29):4557-61, 2007
8. Hochster, H, Luo W, Popa E, Lyman B, Mulcahy M, Beatty P, Benson A. A phase II study of Orzel®
(uft+leucovorin) in elderly (≥ 75 years old) patients with colorectal cancer; Results of Eastern
Cooperative Oncology Group study 1299. J Clin Oncol, 2007, vol 25; J Clin Oncol. 2007 Dec
1;25(34):5397-402. Comment in: J Clin Oncol. 2007 Dec 1;25(34):5350-1.
9. Cohen DJ, Hochster HS. Update on clinical data with regimens inhibiting angiogenesis and epidermal
growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal
Cancer;7 Suppl 1:S21-7, 2007. (review)
10. Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F. Tolerance and
activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian
cancer. A phase I study. Gynecol Oncol. 2008 Mar;108(3):500-4. Epub 2008 Jan 11.
11. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB,
Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and
renal thrombotic microangiopathy. N Engl J Med;358(11):1129-36, 2008.
12. Hochster HS, Hart LL, Ramanath RK, Childs BH, Hainsworth JD, Cohn A, Wong Lucas, Fehrenbacher
L, Abubakir Y, Saif MW, Schwatzberg, L, Hedrick E. Safety and Efficacy of Oxaliplatin–
Fluoropyrimidine Regimens With or Without Bevacizumab as First-Line Treatment of Metastatic
Colorectal Cancer (mCRC): Results of the TREE Study. J. Clin Oncol; 26(21):3523-9, 2008.
13. Cohen DJ, Hochster HS. Update on clinical data with regimens inhibiting angiogenesis and epidermal
growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal
Cancer. Dec;7:21-7, 2007. Review.
14. Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR, Zhang L, Collucci, N,
Horning SJ. Maintenance Rituximab after CVP prolongs PFS in Advanced Indolent Lymphoma –
Results of the randomized phase III E1496 study. Journal of Clinical Oncology, published online ahead
of print Mar 2 2009; (JCO.2008.17.1561)
15. (EDITORIAL) Hochster HS. Stop-and-Go. Yes or No? Journal of Clinical Oncology, Vol 27, No 34,
2009: pp. 5677-5679
D. Research Support
Ongoing Research Support
5P30 CA16087-23 S. Burakoff (PI)
3/1/03 - 2/28/08
NIH/NCI
Cancer Center Support Core Grant
The major goals of this program is to foster, enhance and coordinate the conduct of oncology research,
education and patient activity at NYU Medical Center, and to promote through its programs and specialized
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, first, middle)
Lynch, Thomas J.
shared resources the collaboration and technology transfer intended to more rapidly translate the benefits
of research into more effective approaches to cancer.
Role:
1U01 CA76642-01 F. Muggia (PI)
2/1/98 - 1/31/03
NIH, NCI
No cost extension until 1/31/05
Phase I Studies of Anticancer Drug and Gene Therapy
The development of effective anticancer agents and treatment strategies which will be incorporated into
multidisciplinary, potentially curative treatment protocols for patients with solid tumors.
Role: Co-Investigator
CA21115-27 H. Hochster (PI)
ECOG Operations Office subgrant
Through the NIH ECOG Member Institution
Cooperative group clinical trials.
Role: PI
5/1/01 – 4/30/03
R01-CA111911-01
7/1/05 – 6/30/10
NIH, NCI
Pharmacodynamics of Gemcitabine by Magnetic Resonance Spectroscopy
Use of high field F19-MRS to study intra-tumoral gemcitabine pharmacology in humans
Role: PI
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page